Sumitomo Pharma Co.,Ltd. [4506.T]
TOKYO, May 13 (Pulse News Wire) – Sumitomo Pharma Co., Ltd. (4506.T) reported consolidated results for fiscal year 2026 ending March.
Revenue was ¥450 billion (+13.7% YoY). operating profit was ¥105,908 million (+145.4%).
Net profit attributable to shareholders was ¥106,865 million (+352.1%). Total assets stood at ¥600 billion with an equity ratio of 45.7%.
The full-year forecast for the current fiscal year is revenue of ¥250 billion (+82.9%).
Financial results — FY2026/3 (consolidated)
| Metric | Current | YoY |
|---|---|---|
| Revenue | ¥453,294M | +13.7% |
| Operating profit | ¥105,908M | +145.4% |
| Net profit | ¥106,865M | +352.1% |
Source: TDNet filing · Figures in millions of yen
🟢 Confidence: High AI-translated content.